Skip to content
Megacardsplus Blog

{‘She possesses little expertise’: the US scientific establishment prepares for Dr. Høeg's appointment at the Food and Drug Administration.

As the United States proceeds with sweeping adjustments to its immunization recommendations, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by questioning coronavirus shots throughout the pandemic and has concentrated on possible fatalities after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Program

Public health authorities had intended to reveal sweeping changes to the childhood vaccination calendar earlier this month, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would put the US at odds with much of the international standard with insufficient data for benefit. The planned update has been pushed back until the next year.

In place of the director of the vaccine center, Høeg is scheduled to address the audience at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – traditionally the purview of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Background

The appointee has no obvious experience in medication creation, oversight or administrative roles, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a major agency. She has no expertise in pharmaceutical oversight.”

Former directors of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran the center have had.”

CDER has an vast workload at the FDA, the former commissioner pointed out.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those need to be supervised,” Dr. Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a major administrative aspect to the role, which supervises more than 5,000 employees. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Response and Contentious Initiatives

In response to concerns about Dr. Høeg's qualifications and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “questions stem from flawed assumptions”.

“Her resume is consistent with the duties of her position,” the representative stated, pointing to the time Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's recently launched priority voucher program, a disputed one-day therapy clearance system that allegedly troubled her preceding directors. “By what process are these therapies being picked for this fast-track system? Who makes the choices?” Howard questioned. “There is a lot of lack of transparency going on at the agency right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, aside from vaccines.”

Public Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, history, some experts have noted. She authored a study using non-validated crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the current administration included revising rules for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a podcast. At the FDA, Dr. Høeg has allegedly proposed excluding adolescent males from getting Covid vaccinations.

“She’s an all-around dogmatist who starts off with her preconceived notions and works backwards to fit the evidence in a extremely disingenuous, fraudulent way,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|

By

Kyle Reed

A graphic designer and printing specialist with over 10 years of experience in helping businesses create impactful branding materials.

Megacardsplus Blog

Type to search articles.